FOX News Medical Contributor Dr Marc Siegel joins Fox Business Tonight to discuss the latest Pfizer vaccine data
A CEO at Pfizer has spotted a ‘significant opportunity’ for higher prices of its COVID-19 vaccine when market forces driven by pandemics gradually change.
“If you look at how current demand and current prices are driven, it’s clearly not driven by what I would call normal market conditions, normal market forces,” Pfizer CFO Frank D’Amelio said in a call. “It’s really driven by the kind of pandemic we’re in and the needs of governments to really ensure doses from the different vaccine providers.”
Stocks in this article
D’Amelio said if the pandemic turns into a so-called ‘endemic’ condition, or if livestock vaccinations limit recurrent diseases to certain pockets around the world, a normal market condition will begin to emerge. ‘
MODERNA STARTS TEST OF COVID-19 VACCINE IN CHILDREN UNDER 12
“Factors such as efficacy, enhancement, clinical utility will basically become very important and we honestly consider it an important opportunity for our vaccine from a demand perspective, from a price perspective given the clinical profile of our vaccine,” he said. continued and added. partly: “We think if it moves from pandemic to endemic, we think there’s an opportunity here for us.”
CLICK HERE TO GET FOX BUSINESS ON THE GO
The remarks follow the news that the company is launching a study to determine if a third dose of its COVID-19 vaccine could increase efficacy against coronavirus variants, such as one first detected in South Africa. D’Amelio also noticed an increasing probability of one-time re-vaccinations during the call.